Project Grant R21EB038723
- The National Institutes of Health Office of the Director awarded The Leland Stanford Junior University $231,000 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to advance synthetic biology tools for engineering gut commensal bacteria as therapeutic agents. The project, titled "Advancing Synthetic Biology Tools for Engineering Gut Commensals" (R21EB037892), develops approaches to overcome current limitations in delivering engineered bacterial...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Leland Stanford Junior University $2,421,019 on August 5, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to optimize milli-spinner thrombectomy technology for acute ischemic stroke treatment. The funded work addresses the failure of current thrombectomy devices (aspiration and stent-retrievers) in approximately 15 percent of acute ischemic stroke...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Virginia $190,847 on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop force-based metrics and haptic feedback technology for robotic paraesophageal hernia repair. The research will establish objective performance indicators for complex surgical procedures by integrating force-sensing technology and haptic feedback...
- The National Institutes of Health National Center for Advancing Translational Sciences awarded Intero Biosystems Inc. $349,824 on July 15, 2026, for a Phase I Small Business Innovation Research project to develop a human peristaltic intestinal organoid platform for drug discovery and preclinical testing in gastrointestinal motility disorders. The recipient will engineer and validate a scalable human peristaltic intestinal organoid (peristaltic-HIO) platform that integrates organ-level...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Texas at Austin $618,695 on April 20, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop an adaptive and reconfigurable robot-assisted Single Photon Emission Computed Tomography (SPECT) imaging system. The project focuses on designing, integrating, and validating subsystems for a novel SPECT platform that personalizes imaging...
- The National Institute of Biomedical Imaging and Bioengineering awarded The General Hospital Corporation (Massachusetts General Hospital) $206,250 on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and evaluate the feasibility of an integrated mechano-arthroscope for minimally invasive assessment of joint tissue pathology and micromechanics. The project addresses a gap in arthritis diagnosis: current...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Leland Stanford Junior University $784,530 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to characterize the cellular and molecular architecture of the enteric nervous system under homeostatic and perturbed conditions. The recipient will develop and apply an integrated spatial multi-omics analytical workflow to study the enteric nervous system's...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Regents of the University of California, San Francisco $592,108 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). UCSF will develop and validate stress-sensing microparticles that integrate deformable polymers and mechanomagnetic resonance nanotransducers to enable real-time monitoring of in vivo tissue mechanics with...
- This National Science Foundation (NSF) Project Grant award under the Engineering program (CFDA 47.041) provides $795,932 to the Regents of the University of California at Riverside (UC Riverside) to develop a smart robotic system for comprehensive diagnosis of abnormal tissues in the abdominal cavity. The key products and services to be delivered under this 4-year award include: 1) integrating flexible endoscopy, ultrasound imaging, and Raman spectroscopy into a multimodal instrument for...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Leland Stanford Junior University $217,500 on April 10, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop portable resonance gradient coils for faster MRI with simplified calibration and real-time image reconstruction. The project addresses limitations in MRI encoding speed that constrain exam duration, scheduling availability, and...
The National Institute of Biomedical Imaging and Bioengineering awarded The Leland Stanford Junior University $192,500 for the development and testing of an ingestible robotic device capable of collecting visceral samples from the gastrointestinal tract on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds development of a programmable, swallowable robotic pill (RoboPill) designed to perform active, region-specific collection of gastrointestinal mucus and microenvironmental fluids during natural transit. The device integrates a microcontroller-based wireless control system for on-demand sampling, a hydrodynamic screw mechanism for mucosal capture, and multi-chamber storage enabling sequential sampling from different intestinal regions. The technology targets collection of neurochemicals, extracellular vesicles, proteins, and microbial vesicles that mediate gut-brain signaling—molecules that current clinical tools cannot obtain in spatially resolved samples from the gastrointestinal tract. The project pursues two specific aims: optimizing and validating RoboPill's design, localization, and sequential sampling performance, and evaluating its ability to collect neurochemicals and extracellular vesicles in biomimetic phantoms and ex vivo porcine intestine models. Work is performed in Palo Alto, California with a period of performance from September 1, 2026 through August 31, 2028. Successful completion will establish a minimally invasive tool for spatial mapping of gut-derived signals relevant to brain function and early biomarker identification in neuropsychiatric and neurodevelopmental disease.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $192.5k | 8/25/26 |